Equibles does not estimate personal net worth.
Get an email with a short summary when Corcept Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get CORT alertsRoberto Vieira has spoken on 5 earnings calls across 1 company, most recently for Corcept Therapeutics Inc on November 3, 2026. Corcept Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Corcept Therapeutics Inc includes Joseph K. Belanoff (CEO and Board Member), James N. Wilson (Chairman and Board Member), Atabak Mokari (CFO) and 7 others.
“Lithioli delivered exceptional growth in its second quarter on the market. Revenue grew to $9 to $1.4 million, a 9% to 2% increase. Dement for Lifioli remains strong, reflecting the significant unmet need in platelet-resistant ovarian cancer and growing physician adoption.”
“Lifioli's launch is one of the strongest ever for an oncology medication. The FDA approved Lifioli on March 25th, nearly four months ahead of its PDUFA date. A few dates after that, on April 1st, we sold our first Lifioli capsules.”
“The FDA's approval of Lifioli for the treatment of patients with platinum-resistant ovarian cancer, three and a half months ahead of its Pidufa date, is wonderful news for patients.”
“I want to go back to the point that Joe made in his opening remarks. A 35% reduction in the risk of death, a 4.1-month extension of median overall survival in a population that is incredibly refractory and clinically challenging to treat.”
“So let me just start by saying that since we have presented our data to ASCO, we have had the opportunity to speak with a wide range of key opinion leaders in the field.”
Source not stated
Biotechnology · Healthcare
